vs
EXACT SCIENCES CORP（EXAS）与Rackspace Technology, Inc.（RXT）财务数据对比。点击上方公司名可切换其他公司
EXACT SCIENCES CORP的季度营收约是Rackspace Technology, Inc.的1.3倍（$878.4M vs $682.8M），Rackspace Technology, Inc.净利率更高（-4.8% vs -9.8%，领先5.0%），EXACT SCIENCES CORP同比增速更快（23.1% vs -0.4%），EXACT SCIENCES CORP自由现金流更多（$120.4M vs $56.0M），过去两年EXACT SCIENCES CORP的营收复合增速更高（17.4% vs -0.6%）
Exact Sciences是总部位于美国威斯康星州麦迪逊的分子诊断企业，专注于早期癌症检测领域。公司核心产品覆盖结直肠癌筛查与预防场景，其中Cologuard是全球首个获批的结直肠癌粪便DNA检测产品，同时还提供其他多种癌症的筛查服务及精准肿瘤检测解决方案。
Rackspace Technology, Inc.是总部位于美国得克萨斯州圣安东尼奥的云计算企业，在弗吉尼亚州雷斯顿以及澳大利亚、加拿大、英国、印度、迪拜、瑞士、荷兰、德国、新加坡、墨西哥、中国香港等多个国家和地区设有办事处，数据中心分布于全球多个主要城市，为客户提供专业的云计算相关服务。
EXAS vs RXT — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $878.4M | $682.8M |
| 净利润 | $-86.0M | $-32.7M |
| 毛利率 | 70.1% | 17.6% |
| 营业利润率 | -9.4% | -0.5% |
| 净利率 | -9.8% | -4.8% |
| 营收同比 | 23.1% | -0.4% |
| 净利润同比 | 90.1% | 41.6% |
| 每股收益（稀释后） | $-0.45 | $-0.13 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $878.4M | $682.8M | ||
| Q3 25 | $850.7M | $671.2M | ||
| Q2 25 | $811.1M | $666.3M | ||
| Q1 25 | $706.8M | $665.4M | ||
| Q4 24 | $713.4M | $685.6M | ||
| Q3 24 | $708.7M | $675.8M | ||
| Q2 24 | $699.3M | $684.9M | ||
| Q1 24 | $637.5M | $690.8M |
| Q4 25 | $-86.0M | $-32.7M | ||
| Q3 25 | $-19.6M | $-67.1M | ||
| Q2 25 | $-1.2M | $-54.5M | ||
| Q1 25 | $-101.2M | $-71.5M | ||
| Q4 24 | $-864.6M | $-56.0M | ||
| Q3 24 | $-38.2M | $-186.6M | ||
| Q2 24 | $-15.8M | $25.0M | ||
| Q1 24 | $-110.2M | $-640.6M |
| Q4 25 | 70.1% | 17.6% | ||
| Q3 25 | 68.6% | 19.4% | ||
| Q2 25 | 69.3% | 19.4% | ||
| Q1 25 | 70.8% | 19.1% | ||
| Q4 24 | 69.0% | 19.2% | ||
| Q3 24 | 69.4% | 20.3% | ||
| Q2 24 | 69.8% | 19.2% | ||
| Q1 24 | 70.0% | 19.2% |
| Q4 25 | -9.4% | -0.5% | ||
| Q3 25 | -3.0% | -5.1% | ||
| Q2 25 | -0.3% | -3.8% | ||
| Q1 25 | -13.6% | -5.8% | ||
| Q4 24 | -122.8% | -4.2% | ||
| Q3 24 | -5.6% | -25.7% | ||
| Q2 24 | -3.8% | -7.9% | ||
| Q1 24 | -16.7% | -94.5% |
| Q4 25 | -9.8% | -4.8% | ||
| Q3 25 | -2.3% | -10.0% | ||
| Q2 25 | -0.1% | -8.2% | ||
| Q1 25 | -14.3% | -10.7% | ||
| Q4 24 | -121.2% | -8.2% | ||
| Q3 24 | -5.4% | -27.6% | ||
| Q2 24 | -2.3% | 3.7% | ||
| Q1 24 | -17.3% | -92.7% |
| Q4 25 | $-0.45 | $-0.13 | ||
| Q3 25 | $-0.10 | $-0.28 | ||
| Q2 25 | $-0.01 | $-0.23 | ||
| Q1 25 | $-0.54 | $-0.31 | ||
| Q4 24 | $-4.69 | $-0.20 | ||
| Q3 24 | $-0.21 | $-0.82 | ||
| Q2 24 | $-0.09 | $0.11 | ||
| Q1 24 | $-0.60 | $-2.91 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $964.7M | $105.8M |
| 总债务越低越好 | — | $2.7B |
| 股东权益账面价值 | $2.4B | $-1.2B |
| 总资产 | $5.9B | $2.8B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
| Q4 25 | $964.7M | $105.8M | ||
| Q3 25 | $1.0B | $99.5M | ||
| Q2 25 | $858.4M | $103.9M | ||
| Q1 25 | $786.2M | $128.0M | ||
| Q4 24 | $1.0B | $144.0M | ||
| Q3 24 | $1.0B | $157.1M | ||
| Q2 24 | $946.8M | $190.2M | ||
| Q1 24 | $652.1M | $282.6M |
| Q4 25 | — | $2.7B | ||
| Q3 25 | — | $2.8B | ||
| Q2 25 | — | $2.8B | ||
| Q1 25 | — | $2.8B | ||
| Q4 24 | — | $2.8B | ||
| Q3 24 | — | $2.8B | ||
| Q2 24 | — | $2.9B | ||
| Q1 24 | — | $3.0B |
| Q4 25 | $2.4B | $-1.2B | ||
| Q3 25 | $2.5B | $-1.2B | ||
| Q2 25 | $2.5B | $-1.1B | ||
| Q1 25 | $2.4B | $-1.1B | ||
| Q4 24 | $2.4B | $-1.0B | ||
| Q3 24 | $3.2B | $-949.7M | ||
| Q2 24 | $3.2B | $-756.2M | ||
| Q1 24 | $3.1B | $-787.2M |
| Q4 25 | $5.9B | $2.8B | ||
| Q3 25 | $5.9B | $2.8B | ||
| Q2 25 | $5.8B | $2.9B | ||
| Q1 25 | $5.7B | $3.0B | ||
| Q4 24 | $5.9B | $3.1B | ||
| Q3 24 | $6.7B | $3.1B | ||
| Q2 24 | $6.7B | $3.4B | ||
| Q1 24 | $6.4B | $3.5B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $151.7M | $59.7M |
| 自由现金流经营现金流 - 资本支出 | $120.4M | $56.0M |
| 自由现金流率自由现金流/营收 | 13.7% | 8.2% |
| 资本支出强度资本支出/营收 | 3.6% | 0.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $356.8M | $90.6M |
8季度趋势，按日历期对齐
| Q4 25 | $151.7M | $59.7M | ||
| Q3 25 | $219.9M | $70.7M | ||
| Q2 25 | $89.0M | $8.4M | ||
| Q1 25 | $30.8M | $12.6M | ||
| Q4 24 | $47.1M | $54.3M | ||
| Q3 24 | $138.7M | $51.8M | ||
| Q2 24 | $107.1M | $24.1M | ||
| Q1 24 | $-82.3M | $-90.3M |
| Q4 25 | $120.4M | $56.0M | ||
| Q3 25 | $190.0M | $42.7M | ||
| Q2 25 | $46.7M | $-12.4M | ||
| Q1 25 | $-365.0K | $4.3M | ||
| Q4 24 | $10.7M | $34.4M | ||
| Q3 24 | $112.6M | $27.3M | ||
| Q2 24 | $71.2M | $-14.5M | ||
| Q1 24 | $-120.0M | $-118.4M |
| Q4 25 | 13.7% | 8.2% | ||
| Q3 25 | 22.3% | 6.4% | ||
| Q2 25 | 5.8% | -1.9% | ||
| Q1 25 | -0.1% | 0.6% | ||
| Q4 24 | 1.5% | 5.0% | ||
| Q3 24 | 15.9% | 4.0% | ||
| Q2 24 | 10.2% | -2.1% | ||
| Q1 24 | -18.8% | -17.1% |
| Q4 25 | 3.6% | 0.5% | ||
| Q3 25 | 3.5% | 4.2% | ||
| Q2 25 | 5.2% | 3.1% | ||
| Q1 25 | 4.4% | 1.2% | ||
| Q4 24 | 5.1% | 2.9% | ||
| Q3 24 | 3.7% | 3.6% | ||
| Q2 24 | 5.1% | 5.6% | ||
| Q1 24 | 5.9% | 4.1% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 0.96× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EXAS
| Screening | $695.1M | 79% |
| Precision Oncology | $183.2M | 21% |
RXT
| Public Cloud Services Segment | $442.2M | 65% |
| Private Cloud Service Segment | $240.6M | 35% |
